FDA grants Ultragenyx accelerated approval for GENGLYCOS in GSDIa patients 8 and older

PUBT · 1d ago
FDA grants Ultragenyx accelerated approval for GENGLYCOS in GSDIa patients 8 and older
  • Ultragenyx won FDA accelerated approval for GENGLYCOS (DTX401) in glycogen storage disease type Ia patients aged 8 and older.
  • Clearance rests on 48-week Phase 3 data showing reduced cornstarch requirements versus placebo (p<0.001).
  • Post-marketing commitment: 2-year open-label follow-up in 50 treated patients, with 20 antibody-positive controls, tracked via its monitoring program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-357185), on August 19, 2026, and is solely responsible for the information contained therein.